Objective  To explore the clinical efficacy and safety of probiotic-assisted chemotherapy in patients advanced colorectal cancer (CRC).

Methods  Patients with advanced CRC admitted to the First Affiliated Hospital of Hunan Normal University from March 2022 to March 2023 were enrolled. CRC patients were randomly divided into the test group (Bifidobacterium triple viable capsule, capecitabine+oxaliplatin) and the control group (capecitabine+oxaliplatin) by random number table method. The short-term efficacy (objective response rate and disease control rate), incidence of gastrointestinal adverse reactions, Karnofsky performance status (KPS) score, and serum tumor markers CA72-4, CA19-9 and CEA levels were compared between the two groups.

Results  A total of 120 patients with CRC were included, including 60 patients in the test group and 60 in the control group. Compared with the control group, the objective remission rate and disease control rate in the testl group were significantly higher (P<0.05). There was no significant difference in the incidence of nausea and acid reflux between the two groups (P>0.05), and the incidences of abdominal pain, bloating, constipation and diarrhea in the test group were significantly lower than those in the control group (P<0.05). There was no significant difference in KPS score, serum CA72-4, serum CA19-9 and serum CEA levels between the two groups before treatment (P>0.05), and after 4 weeks of treatment, the KPS score of the test group was significantly higher than that of the control group (P<0.05), and the serum levels of CA72-4, serum CA19-9 and serum CEA were lower than those of the control group (P<0.05).

Conclusion  Probiotics-assisted chemotherapy improve the near-term efficacy, reduce gastrointestinal adverse effects, and improve the quality of life in patients with advanced CRC.

1.Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48. DOI: 10.3322/caac.21763.

2.Benson AB, Venook AP, Al-Hawary MM, et al. Colon Cancer, Version 2. 2021, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2021, 19(3): 329-359. DOI: 10.6004/jnccn.2021.0012.

3.Yoshino T, Arnold D, Taniguchi H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS[J]. Ann Oncol, 2018, 29(1): 44-70. DOI: 10.1093/annonc/mdx738.

4.中华医学会肿瘤学分会, 国家卫生健康委员会医政司. 中国结直肠癌诊疗规范(2023版)[J]. 协和医学杂志, 2023, 14(4): 706-733. DOI: 10.12290/xhyxzz.2023-0315.

5.Yixia Y, Sripetchwandee J, Chattipakorn N, et al. The alterations of microbiota and pathological conditions in the gut of patients with colorectal cancer undergoing chemotherapy[J]. Anaerobe, 2021, 68: 102361. DOI: 10.1016/j.anaerobe.2021.102361.

6.徐炜, 屠建国, 王际云, 等. 龟鹿二仙胶加味辅助化疗治疗晚期大肠癌疗效及对免疫功能及生存质量的影响[J]. 中华中医药学刊, 2022, 40(3): 229-232. [Xu W, Tu JG, Wang JY, et al. The therapeutic effect of Gui Lu Er Xian Jiao modified adjuvant chemotherapy on advanced colorectal cancer and its impact on immune function and quality of life[J]. Chinese Journal of Traditional Chinese Medicine, 2022, 40(3): 229-232.] DOI: 10.13193/j.issn. 1673-7717.2022.03.053.

7.梁凤仪, 郭成成, 罗梁玉, 等. 肠道菌群在结直肠癌中的研究进展[J]. 中国医药科学, 2023, 13(19): 62-65, 82. [Liang FY, Guo CC, Luo LY, et al. Research progress of gut microbiota in colorectal cancer[J]. Chinese Medical Science, 2023, 13(19): 62-65, 82.] DOI: 10.20116/j.issn 2095-0616.2023.19.13.

8.杨秋燕, 肖海娟, 马玉媛, 等. 化疗恶心、呕吐发生和治疗与肠道菌群相关性的研究进展[J]. 中国医药导报, 2023, 20(32): 43-46. [Yang QY, Xiao HJ, Ma YY, et al. Research progress on the correlation between the occurrence and treatment of chemotherapy induced nausea and vomiting and gut microbiota[J]. China Medical Journal, 2023, 20(32): 43-46.] DOI: 10.20047/j.issn1673-7210. 2023.32.08.

9.张连忠. 植物乳杆菌对感染肠毒性大肠杆菌断奶猪生长性能、绒毛形态及粪微生物含量的影响[J]. 中国饲料, 2021, (18): 45-48. [Zhang LZ. The effects of Lactobacillus plantarum on the growth performance, villus morphology, and fecal microbiota content of weaned pigs infected with enterotoxic Escherichia coli[J]. Chinese Feed, 2021, (18): 45-48.] DOI: 10.15906/j. cnki.cn11-2975/s.20211812.

10.刘红霞, 李雪利, 吴秀英, 等. 后生元研究进展及应用现状[J]. 食品科学, 2024, 45(1): 326-333. [Liu HX, Li XL, Wu XY, et al. Research progress and application status of epigenetic elements[J]. Food Science, 2024, 45(1): 326-333.] DOI: 10.7506/spkx1002-6630-20221229-272.

11.陈俊飞, 陈健豪, 曹佩江. 益生菌补充剂与人体免疫调节功能[J]. 科技导报, 2023, 41(23): 14-19. [Chen JF, Chen JH, Cao PJ. Probiotic supplements and human immune regulatory function[J]. Technology Review, 2023, 41(23): 14-19.] DOI: 10.3981/j.issn.1000-7857. 2023.23.002.

12.Razali NN, Ali RAR, Nawawi KNM, et al. Targeted sequencing of cytokine-induced PI3K-related genes in ulcerative colitis, colorectal cancer and colitis-associated cancer[J]. Int J Mol Sci, 2022, 23(19): 11472. DOI: 10.3390/ijms231911472.

13.Raoul P, Cintoni M, Palombaro M, et al. Food additives, a key environmental factor in the development of IBD through gut dysbiosis[J]. Microorganisms, 2022, 10(1): 167. DOI: 10.3390/microorganisms10010167.

14.张扬, 徐琼, 胡洁品, 等. 益生菌辅助治疗结直肠癌有效性和安全性的系统评价和试验序贯分析[C]. 成都: 亚洲营养学会联合会、中国营养学会, 2023.

15.Wong CC, Yu J. Gut microbiota in colorectal cancer development and therapy[J]. Nat Rev Clin Oncol, 2023, 20(7): 429-452. DOI: 10.1038/s41571-023-00766-x.

16.Liu H, Zhang K, Liu P, et al. Improvement effect of bifidobacterium animalis subsp. lactis MH-02in patients receiving resection of colorectal polyps: a randomized, double-blind, placebo-controlled trial[J]. Front Immunol, 2022, 13: 940500. DOI: 10.3389/fimmu.2022.940500.

17.郑辞华. 益生菌复配制剂对胃癌术后患者的辅助治疗及其机制研究[D]. 南昌: 南昌大学, 2020.

18.刘玉曼, 李淑莹, 燎原. 益生菌在新辅助化疗+胃癌根治术老年患者中的应用效果[J]. 癌症进展, 2023, 21(19): 2147-2149, 2173. [Liu YM, Li SY, Liao Y. The application effect of probiotics in elderly patients undergoing neoadjuvant chemotherapy and gastric cancer radical surgery[J]. Cancer Progression, 2023, 21(19): 2147-2149, 2173.] DOI: 10.11877/j. issn.1672-1535.2023.21.19.15.

19.蔡曌颖, 朱冬徐, 周若宇, 等. SERS光谱技术在结直肠癌诊断中的应用效果[J]. 微纳电子技术, 2024, 61(2): 151-158. [Cai ZY, Zhu DX, Zhou RY, et al. The application effect of SERS spectroscopy technology in the diagnosis of colorectal cancer[J]. Microelectronics and Nanoelectronics Technology, 2024, 61(2): 151-158.] DOI: 10.13250/j. cnki.wndz.24020502.

20.武天同. CEA、CA19-9和CA72-4联检在结直肠癌预后中的临床研究[D]. 广州: 南方医科大学, 2021.

21.迪米拉·阿里根, 帕尔哈提·阿布都热衣木, 张丽博. 双歧杆菌三联活菌辅助XELOX方案对结直肠癌术后抗肿瘤免疫应答和肿瘤标志物的影响[J]. 中国临床研究, 2019, 32(4): 516-519. [Dimira Arigen, Parhati Abudureimu, Zhang LB. The effect of bifidobacterium triple live bacteria assisted XELOX regimen on postoperative anti-tumor immune response and tumor markers in colorectal cancer[J]. Chinese Clinical Research, 2019, 32(4): 516-519.] DOI: 10.13429/j.cnki.cjcr.2019.04.020.

22.Jiang H, Li J, Zhang B, et al. Intestinal flora disruption and novel biomarkers associated with nasopharyngeal carcinoma[J]. Front Oncol, 2019, 9: 1346. DOI: 10.3389/fonc.2019.01346.

23.Al Bander Z, Nitert MD, Mousa A, et al. The gut microbiota and inflammation: an overview[J]. Int J Environ Res Public Health, 2020, 17(20): 7618. DOI: 10.3390/ijerph17207618.

24.Frei R, Akdis M, O'Mahony L. Prebiotics, probiotics, synbiotics, and the immune system: experimental data and clinical evidence[J]. Curr Opin Gastroenterol, 2015, 31(2): 153-158. DOI: 10.1097/MOG.0000000000000151.